Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis.
Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.
Bradley
Walter G
WG
Department of Neurology, Miller School of Medicine, University of Miami, 1120 NW 14 Street, Miami, Florida 33136, USA. wbradley@med.miami.edu
D000596:Amino Acids / Q000627:therapeutic use; D000599:Amino Acids, Diamino / Q000032:analysis / Q000378:metabolism / Q000633:toxicity*; D000600:Amino Acids, Dicarboxylic / Q000032:analysis / Q000378:metabolism / Q000633:toxicity*; D000604:Amino Acyl-tRNA Synthetases / Q000037:antagonists & inhibitors / Q000187:drug effects; D000690:Amyotrophic Lateral Sclerosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy*; D000458:Cyanobacteria / Q000737:chemistry / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006197:Hair / Q000737:chemistry; D006801:Humans; D009498:Neurotoxins / Q000032:analysis / Q000378:metabolism / Q000633:toxicity*; D021381:Protein Transport / Q000187:drug effects
D000596:Amino Acids; D000599:Amino Acids, Diamino; D000600:Amino Acids, Dicarboxylic; D004791:Enzyme Inhibitors; D009498:Neurotoxins; C064612:alpha-N-carboxy-beta-N-methylaminoalanine; D000604:Amino Acyl-tRNA Synthetases